Abstract
Objective: To determine completeness and validity of data submitted via automated electronic health record (EHR) interface for the California Parkinson’s Disease Registry (CDPR).
Background: CPDR requires all California clinicians to report patients diagnosed with Parkinson’s disease (PD). To facilitate, an EHR-based algorithm identified PD cases and automatically reported required data to CDPR without user actions.
Design/Methods: We manually reviewed 444 randomly selected patients identified based on six PD and parkinsonism ICD10 codes (to compare with two CPDR required codes G20, G90.3), seen at UCLA between 10/1/18 and 12/31/18. Review was conducted by research assistants and supervised by 2 neurologists. Each patient was classified as “Definite PD,” “Possible PD,” or “Not PD” based on documented clinician impression with additional review by neurologists who considered signs, symptoms, treatment responses. For “Definite PD,” we abstracted date of diagnosis as earliest date when PD was documented.
Results: Six ICD10 codes identified 5% more PD cases compared to two CPDR codes. CPDR reported cases had a positive predictive value of 79% for “Definite PD;” 14% cases were “Not PD.” Unexpectedly, we found 25% of “Definite PD” were not reported to CPDR, resulting in 71% sensitivity and 34% specificity. Comparing EHR and abstracted date of diagnosis, 6% of cases matched month-year; 20% cases were within 1 year. The range of date differences was large with 13% being >10 years apart.
Conclusions: Results identified case underreporting, moderate sensitivity and very low specificity for this automated submission to CPDR. Validity of EHR-extracted date of diagnosis was poor and likely depends on EHR implementation and improves with newly diagnosed case selection. CPDR has successfully launched a mandatory state-wide registry for PD with automated EHR interfaces. Iterative and ongoing improvements in interface, algorithm, and workflow designs with validation are required for CPDR to reach its potential as a valid and high-quality population-level PD registry.
Disclosure: Dr. Wu has nothing to disclose. Dr. Malatt has nothing to disclose. Dr. Truong has nothing to disclose. Dr. Wu has nothing to disclose. Dr. Bryant-Dunmire has nothing to disclose. Dr. Agosta has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen Idec, Novartis.Dr. Ritz has nothing to disclose. Dr. Tanner has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Voyager Therapeutics, Intec Pharma, Neurocrine Biosciences, Adamas Therapeutics, Grey Matter, CNS Ratings, Acorda, Amneal. Dr. Tanner has received research support from BioElectron, Roche/Genentech, Biogen Idec , Gateway LLC.Dr. Cheng has nothing to disclose.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
